EP Patent

EP2832351A1 — Multilayer Tablet Formulations Comprising Tenofovir and Entecavir

Assigned to Arven Ilac Sanayi ve Ticaret AS · Expires 2015-02-04 · 11y expired

What this patent protects

The present invention relates to a multilayer tablet formulation comprising tenofovir or a pharmaceutically acceptable salt thereof and entecavir or a pharmaceutically acceptable salt thereof. The present invention further relates to a process for preparing such a formulation and…

USPTO Abstract

The present invention relates to a multilayer tablet formulation comprising tenofovir or a pharmaceutically acceptable salt thereof and entecavir or a pharmaceutically acceptable salt thereof. The present invention further relates to a process for preparing such a formulation and to the use thereof in the treatment of chronic hepatitis B.

Drugs covered by this patent

Patent Metadata

Patent number
EP2832351A1
Jurisdiction
EP
Classification
—
Expires
2015-02-04
Drug substance claim
No
Drug product claim
No
Assignee
Arven Ilac Sanayi ve Ticaret AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.